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Summary
Background: Hepatitis B virus (HBV) infection is common with major clinical conse-
quences. In Asian Americans, the HBsAg carrier rate ranges from 2% to 16% which
approximates the rates from their countries of origin. Similarly, HBV is the most
important cause of cirrhosis, hepatocellular carcinoma (HCC) and liver related deaths
in HBsAg positive Asians worldwide.
Aim: To generate recommendations for the management of Asian Americans
infected with HBV.
Methods: These guidelines are based on relevant data derived from medical reports
on HBV from Asian countries as well as from studies in the HBsAg positive Asian
Americans. The guidelines herein differ from other recommendations in the treat-
ment of both HBeAg positive and negative chronic hepatitis B (CHB), in the
approach to HCC surveillance, and in the management of HBV in pregnant women.
Results: Asian American patients, HBeAg positive or negative, with HBV DNA
levels >2000 IU/mL (>104 copies/mL) and ALT values above normal are candidates
for anti-viral therapy. HBeAg negative patients with HBV DNA >2000 IU/mL and
normal ALT levels but who have either serum albumin <3.5 g/dL or platelet count
<130 000 mm3, basal core promoter (BCP) mutations, or who have first-degree rela-
tives with HCC should be offered treatment. Patients with cirrhosis and detectable
HBV DNA must receive life-long anti-viral therapy. Indications for treatment include
pregnant women with high viraemia, coinfected patients, and those requiring
immunosuppressive therapy. In HBsAg positive patients with risk factors, life-long
surveillance for HCC with alpha-fetoprotein (AFP) testing and abdominal ultrasound
examination at 6-month intervals is required. In CHB patients receiving HCC treat-
ments, repeat imaging with contrast CT scan or MRI at 3-month intervals is strongly
recommended. These guidelines have been assigned to a Class (reflecting benefit vs.
risk) and a Level (assessing strength or certainty) of evidence.
Conclusions: Application of the recommendations made based on a review of the
relevant literature and the opinion of a panel of Asian American physicians with
expertise in HBV treatment will inform physicians and improve patient outcomes.
The Handling Editor for this article was Professor Grace Wong, and it was accepted for publication after full peer-review.
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1 | INTRODUCTION
Hepatitis B virus infection is common and clinically consequential
worldwide. The prevalence of HBV carriers globally ranges from
240 million to 300 million persons.1,2 An estimated 75% of these
infected individuals reside in the Asia-Pacific region wherein HBV
is responsible for up to one-third of all cases of cirrhosis and over
50% of HCC cases. HBV infection is a major public health problem
in the USA, especially among ethnic minorities. The prevalence of
HBsAg positive persons in the USA is estimated to be 2.2 million
persons. Of these, 1.32 million are foreign born with 58% immi-
grating from high or intermediate endemic areas of Asia.3 At pre-
sent, immigrants account for 95% of newly diagnosed HBV
infections in the USA.4 As a result, Asian Americans are the ethnic
group with the highest prevalence of HBV, and have the highest
rates of HCC incidence and mortality in this country. A recent
study in 400 HBsAg positive Asian American patients showed that
during a mean 84-month follow-up, 67 of 71 (94%) deaths were
from either liver-related complications or HCC.5 Recent reports
indicate that both screening for HBV in the Asian American popu-
lation and linkage to health care have been suboptimal.6,7 Despite
the availability of potent anti-viral medications, improving the mor-
bidity and mortality rates associated with HBV in Asian Americans
require greater emphasis on HBV education among health care pro-
viders.
2 | METHODS
In April 2016, a panel of Asian American physicians with expertise
in the management of HBV convened in Pasadena, CA. Each mem-
ber was pre-assigned a section and instructed to review the rele-
vant medical literature specifically aimed at Asian and Asian
Americans with hepatitis B infection. During the meeting, each
topic was presented and subsequently, the manuscript was com-
piled and edited (MJT). The manuscript was reviewed by the
authors and a consensus on management of Hepatitis B in Asian
Americans was finalised.
Unique for Asians and Asian Americans with CHB include mater-
nal to child transmission (MTCT), the long period of chronicity begin-
ning in the immune tolerant stage with high viraemia, presence of
genotypes B or C, and the high rate of progression to liver related
complications and HCC. More recently, disparities in HCC survival
was reported in a subgroup of first generation Asian immigrants to
the USA, specifically due to paucity of medical care, lack of hepatitis
B screening and treatments, and late stage of HCC presentation.8
Thus, the aim of this manuscript is to review the natural history,
virology and clinical characteristics as it pertains to the approach,
management and treatment of Asian Americans with chronic hepati-
tis B. It is anticipated that the information herein will assist physi-
cians in the day to day management of CHB in the Asian American
population.
3 | QUALITY OF EVIDENCE
This document was intended to provide recommendations regarding
the management of CHB infection in adult Asian Americans. Recom-
mendations set forth herein have been assigned to a Class (reflecting
benefit vs risk) and a Level (assessing strength or certainty) of evi-
dence according to the grading system set forth in the 2015 update
of the American College of Cardiology/American Heart Association
Clinical Practice Guideline Recommendation Classification System
(Data S1).9
4 | EPIDEMIOLOGY, NATURAL HISTORY,
CLINICAL STAGES AND PROGRESSION OF
DISEASE IN ASIANS
4.1 | Prevalence of HBsAg
Hepatitis B virus carrier rates in Asia have been reported to be as
high as 20% in the male population of Guang Xi Province and up to
27.5% in the Fujian Province of China.10 HBV carrier rates ranging
from 10% to 15% have been reported in Hong Kong, Shanghai, Tai-
wan and Southeast Asia.11 According to the results of a recent study
from China, HBV carrier rates have fallen to 7.2% in regions where
HBV vaccination programmes have been implemented.12 The report
also indicated that the carrier rate in children <5 years of age had
decreased from 9.7% in 1992 to 1% in 2006, thus preventing an
estimated 16-20 million HBV carriers through HBV vaccination of
infants and young children. A similar study in Taiwan showed a
decrease in the HBV carrier rate in children from 10% in 1984 to
0.5% in 2009 as well as in the childhood HCC rate after implementa-
tion of HBV vaccination of infants at birth.13 However, in other
parts of Asia, the HBsAg carrier rates remain high, particularly in
countries in which HBV vaccine programmes have not yet been
implemented. In these endemic areas, 80% of patients with chronic
hepatitis, 92% with cirrhosis, and 80% with HCC are HBsAg posi-
tive.14-19
Notably, the HBsAg carrier rates among Asian Americans are
similar to rates reported in their countries of origin, especially in first
generation immigrants to the USA3,12,19,20 Table 1 shows a compar-
ison of HBsAg prevalence rates derived from screening programmes
in various cities in the USA, to a study which derived the HBsAg car-
rier rates by estimating the number of foreign born persons in the
USA and the prevalence of HBsAg carriers reported from their
native countries.3
4.2 | Routes of infection
In high and intermediate HBV endemic areas (HBsAg prevalence
rates of ≥8% and 2%-7% respectively) in Asia, HBV infection takes
place from mother to child during birth. Up to 90% of infants
born to HBeAg positive mothers with high viraemia become
chronically infected if immunoprophylaxis is not administered at
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birth. In low endemic areas (HBsAg prevalence rates <2%), expo-
sure to HBV occurs primarily among adolescents and adults, in
whom the carrier rate following acute infection is <5%. In Asian
adults, sexual contact may account for up to 10% of all HBV carri-
ers. HBV transmission also occurs at high rates among injection
drug users in Asia.21
4.3 | The phases of CHB infection
In Asian patients, the natural course of CHB infection can be divided
into five distinct phases which include the immune tolerant, immune
activation, low replication phase, reactivation and the clinical resolu-
tion phase (Figure 1). A description of the five phases is provided in
Data S2.
4.4 | The clinical stages of CHB infection
Based on HBeAg status, as well as ALT and HBV DNA levels at pre-
sentation, patients may be classified into one of several clinical
stages of HBV infection (Figure 2).22 During subsequent visits,
changes in the patient’s virological and biochemical parameters may
clarify the patient’s clinical status, especially regarding the evaluation
of disease progression and assessment of the need for anti-viral
therapy. The six clinical stages include: HBeAg positive immune tol-
erant, chronic hepatitis and cirrhosis patients, and the HBeAg nega-
tive low replication carrier, chronic hepatitis and cirrhosis patients.
These clinical stages are further characterised in Table S1.
4.5 | Predictors of disease progression
The annual rates of progression from chronic hepatitis to cirrhosis,
decompensated cirrhosis, HCC and death are shown on Figure S1
and described in Data S3. Serologic predictors of disease progression
in CHB patients include HBeAg, HBV genotype, HBV DNA titres,
BCP mutants and PC mutants. A description of each of these factors
are shown in Table S2. Tests for HBV genotype, BCP mutants and
PC mutants are readily available at commercial laboratories in the
USA. In addition, serum AFP levels are elevated in patients with
acute and chronic liver diseases in the absence of HCC, especially in
the presence of ongoing necroinflammation.23,24 Elevation of AFP
levels during ALT flares was detected in CHB-infected patients who
eventually developed cirrhosis, and thus is another parameter to use
when evaluating patients for anti-viral therapy.25
4.6 | Family history of HCC
In a recent study, of 413 Asian American HBsAg positive patients,
173 with HCC and 240 without HCC were sub grouped into those
with or without a family history of HCC and analysed for risk factors
associated with HCC development.25 Forty-four of 173 (25.4%) HCC
patients had 82 other blood relatives with HCC. Of these, 69
(84.1%) were first degree relatives. In a multivariate logistic regres-
sion model, a family history of HCC was an independent factor asso-
ciated with HCC development (OR = 2.58, P = 0.048). In addition, in
a large population-based cohort study of 22 472 participants from
Taiwan, 374 cases of incident HCC were identified during 362 268
person-years of follow-up.26 The multivariate-adjusted hazard ratio
for HCC for HBsAg positive individuals with family history of HCC
was 32.33 (P < 0.001), confirming a synergistic effect of family his-
tory and HBV on incidence of HCC.
5 | SURVEILLANCE FOR HCC IN ASIAN
PATIENTS WITH CHB INFECTION
Patients with CHB infection have a > 100-fold increased risk for the
development of HCC compared with those without HBV infec-
tion.27,28 The annual incidence of HCC in low replication carriers is
estimated to be 0.5% and increases to 3%-10% in patients with cir-
rhosis.29 The REVEAL study from Taiwan by Chen et al demon-
strated a strong correlation between increasing HBV DNA levels
beginning at >2000 IU/mL (>104 copies/mL) and risk for HCC.27,30
Another report on 820 patients with CHB infection from Hong Kong
showed that male gender, increasing age, higher HBV DNA levels,
presence of BCP mutations, and cirrhosis were independent risk fac-
tors for HCC.31 In a predominantly Asian American population, risk
factors for HCC included older age, cirrhosis, PC mutations, BCP
mutations, and high serum AFP levels.32-34
A randomised controlled trial for HCC screening in >18 000 sub-
jects in Shanghai, China showed a 37% reduction in HCC-related
mortality among patients detected by surveillance.35 Another recent
study in Asian Americans with HBV showed that surveillance identi-
fied HCC patients with smaller tumour burdens and better preserved
liver function who were more likely to receive curative therapies
which prolonged survival.36
Surveillance for HCC in all HBsAg positive patients should
include both AFP testing and abdominal ultrasound examination (Fig-
ure 3). However, lesion detection rates by ultrasound may be com-
promised by body habitus, fatty liver and cirrhosis.37 Therefore,
cross sectional imaging with contrast enhanced computed
TABLE 1 The prevalence of HBsAg in Asian Americans
Country of origin Screening in the USA
Derived from prevalence
in country of origin
China 5.6%-12.3% 12.3%
Vietnam 3.2%-13.6% 12.8%
Philippines 5.5%-7.4% 7.4%
South Korea 5.3% 5.3%
Laos 2.3%-16.4% 11.6%
Burma 9.4%-12.4% 11.6%
Cambodian 10.3% 13.6%
Thailand 3.9%-6.1% 12.5%
Malaysia 8.8% 5.6%
India 1.5% 3.2%
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tomography (CT) or magnetic resonance imaging (MRI) should be
considered in a surveillance programme whenever the image quality
of an ultrasound is suboptimal (Figure S2). HBsAg positive patients
at high risk for HCC development include those with more advanced
stage of liver disease, ie, chronic hepatitis, cirrhosis and those with
blood relatives with HCC.25,38 Patients with low-to-moderate risk
include low replication carriers and immune tolerant patients. In
addition, since patients who clear HBsAg may still develop HCC,
surveillance should be continued, especially if cirrhosis is present at
the time of HBsAg loss.39 The current recommendation for HCC
surveillance is every 6-12 months in immune tolerant and low repli-
cation carriers, and every 6 months in chronic hepatitis and cirrhosis
patients (Figure 4). In patients with persistently elevated AFP levels
with undetectable lesions by ultrasound examination and in patients
receiving HCC treatment, surveillance should include contrast CT
scan or MRI at 3-month intervals, which is based on the average
HCC doubling time of 4.3 months.40
Although debate remains regarding the optimal age to begin
HCC surveillance, it is probably not warranted among paediatric
patients because of the low risk of HCC. The benefit of surveillance
in HBsAg positive males aged <40 years and females aged <50 years
has not been determined. However, up to 20% of HCC cases in
Asians may be in this younger age range. If clinically active chronic
hepatitis infection, cirrhosis or other risk factors for HCC are pre-
sent, then surveillance for HCC should be instituted.36,41,42
Further management guidelines for liver lesions detected by
surveillance are presented in Data S4. Confirmed cases of HCC must
be referred to a multidisciplinary centre consisting of hepatologists,
surgeons, interventional radiologists and oncologists who specialise
in the treatments of this malignancy (Table S3).43 We recommend
HBsAg–HBsAg+
HBeAg+ anti-HBe+ anti-HBe+
HBV DNA
ALT
Immune
tolerant
Immune
activation
Low
replication Reactivation Resolution
Minimal
inflammation
Active
inflammation
Mild
inflammation
Active
inflammation Inactive
PC mutation/
BCP mutation
Reactivation
Wild type
reactivation F IGURE 1 The five phases of chronic
hepatitis B infection
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F IGURE 2 The clinical stages of
hepatitis B
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that during the initial workup of a new HBsAg positive patient, a
baseline abdominal ultrasound and AFP measurement should be
obtained. Thereafter, routine HCC surveillance with the above tests
must be performed at the recommended intervals.
6 | TREATMENT OF CHB INFECTION IN
ASIAN AMERICANS: PROPOSED
CANDIDATES FOR TREATMENT BASED ON
CLINICAL STAGE
The goal of anti-viral therapy in patients infected with HBV is to
prevent progression from chronic hepatitis to cirrhosis, end-stage
liver disease, and development of HCC. The eligibility for anti-viral
therapy in recently published guidelines is based on HBeAg status,
ALT values, and levels of HBV DNA in the setting of either chronic
hepatitis or cirrhosis.44-47
6.1 | The significance of ALT
Elevated serum ALT levels are indicators of hepatic necroinflammatory
activity. Because studies have shown that an elevated pre-treatment
ALT level was a significant predictor of HBeAg loss or seroconversion
to treatments with interferon,48,49 pegylated-interferon alfa-2a,50 lami-
vudine (LAM),51,52 and adefovir (ADV),53 all of the published guidelines
recommend anti-viral therapy for patients with CHB infection who have
elevated ALT levels. However, a significant proportion of CHB-infected
patients with normal to minimally increased ALT levels may have signifi-
cant inflammation and fibrosis on liver biopsy.54-57 Also, a meta-analysis
demonstrated that approximately one in five patients with persistently
normal ALT had fibrosis scores of F2 or higher.58 Finally, a study from
Hong Kong which included 3,233 CHB patients followed up for over
180 months were stratified by ALT level at presentation and during fol-
low-up (<0.5 9 ULN, 0.5-1 9 ULN, 1-2 9 ULN, 2-6 9 ULN and
>6 9 ULN) and observed for development of decompensated cirrhosis
or HCC.59 The highest risk of complications was associated with ALT
levels 1–2 9 ULN, followed by lesser risks in patients with ALT levels
2–6 9 ULN, and 0.5–1 9 ULN.
6.2 | The significance of HBV DNA
The advent of PCR-based assays with improved sensitivity heralded
the era of serum HBV DNA as a marker of disease progression.
HBeAg positive patients and many HBeAg negative patients have
HBV DNA levels below 105 copies/mL.60 From 2001 through 2006,
several studies noted the development of HCC in cirrhotic and non-
cirrhotic patients with CHB infection with HBV DNA levels as low
as 3.7 log10 copies/mL.
5,61-63 In 2006, Chen et al published a study
of 3653 HBsAg positive patients followed up for a mean of
11.4 years which showed that the incidence of HCC increased with
serum HBV DNA levels at study entry in a dose-related fashion.27 In
a parallel publication, Iloeje and colleagues demonstrated a similar
relationship between serum HBV DNA and the development of cir-
rhosis.64 In both studies, there was an increased risk of progression
to cirrhosis and development of HCC at HBV DNA levels above 104
copies/mL. Since then, additional studies have confirmed a serum
HBV DNA level >4 log10 copies/mL as predictive of an increased risk
for HCC development.65,66
6.3 | Criteria from current guidelines and new era
for a more comprehensive treatment strategy
Several recently published guidelines and an expert consensus algo-
rithm focusing on the treatment of CHB infection are summarised in
Table S4. The difference in selection of HBV patients for anti-viral
therapy in these published guidelines are discussed in Data S5. In a
long term, natural history study of predominantly Asian CHB-
infected patients in the USA by Tong et al, the treatment criteria
designated in the established treatment guidelines were applied to a
cohort of 369 HBsAg positive patients followed up for a mean of
84 months (7 years).67 Using the threshold, HBV DNA and ALT val-
ues stated in the published documents, only 20%-60% of patients
who developed HCC and 27%-70% who died from or were trans-
planted for non-HCC-related liver complications would have been
identified initially as anti-viral treatment candidates. Previously, Tong
et al reported on a cohort of 400 CHB-infected patients in the USA
followed up for a mean of 83.6 months.5 The results of a multivari-
ate analysis showed that older age (OR = 26.51, P = 0.007), PC
mutants (OR = 4.23, P = 0.02), and BCP mutants (OR = 2.93,
P = 0.02) were independent predictors for HCC. Additional studies
on PC and BCP mutants are discussed in Data S6.
Recently, Chen et al showed that lower serum albumin
levels was an independent risk factor for HCC development.27 In the
aforementioned study by Tong et al,67 the addition of a platelet
count <130 000 mm3 and serum albumin value <3.5 g/dL to the cri-
teria established by the published treatment guidelines increased the
detection rate of patients eligible for treatment to 89%-100% of
patients who died of non-HCC liver-related causes and 96%-100%
of patients who developed HCC.
F IGURE 3 Ultrasound detection of a 3 cm HCC
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6.4 | Recommendations for treatment in Asian
American patients with chronic hepatitis B
At present, anti-viral treatment is not recommended for patients who
are in the immune tolerant stage or in low replication carriers. Our
guidelines are illustrated in a new algorithm, which includes additional
laboratory parameters to better identify candidates for treatment to
prevent disease progression (Table 2 and Figure 5). The algorithm
specifies a quantitative HBV DNA threshold of 2000 IU/mL as the
initial determination to consider treatment in both HBeAg positive
and HBeAg negative patients, primarily based on data from the
REVEAL-HBV study from Taiwan indicating 104 copies/mL (2000 IU/
mL) as the threshold HBV DNA level predictive of future cirrhosis
and HCC development.27 In patients with an HBV DNA quantitation
above this threshold level, determination of serum ALT is the next
decision point for treatment. Patients with an ALT value > ULN in
the physician’s local laboratory in conjunction with an elevated serum
HBV DNA would be eligible for consideration of anti-viral therapy.
ALT values of 30 U/L for men and 19 U/L for women were
established as the ULN in healthy patients with the lowest risk for
Cirrhosis
No
Yes
No
No
No
Yes
Yes
Immune tolerant
Low replication carrier Chronic hepatitis
AFP
HCC**
Risk factors*
AFP and ultrasound
examination every
12 mo+
AFP and ultrasound
examination every
6 mo+
AFP and CT scan
or MRI 3 mo
*Risk factors; Family history of HCC, Basal core
promoter mutant, diabetes, NASH, HCV or HIV
coinfection
**Ongoing HCC treatment
+ If ultrasound examination suboptimal,
proceed with contrast CT scan or MRI
AFP: alpha-fetoprotein
HCC: Hepatocellular carinoma
CT: Computerized tornography
MRI: Magnetic resonance imaging
F IGURE 4 HCC surveillance intervals in
Asian patients with hepatitis B
HBV DNA ALT
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>2000 IU/mL
≤ULN
≤ULN
≥ Fibrosis stage 2**
>ULN
>ULN
Re-evaluate in 3-6 mo
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Alcohol intake
Other viral etiologies ++
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         laboratory
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***Based on data from Asian patients
F IGURE 5 Treatment algorithm for
HBsAg positive patients with HBeAg
positive/negative chronic hepatitis B
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subclinical liver disease68 and are used as the ULN determination in
the AASLD guidelines and US algorithm. However, in real-world
practice, ALT values often exceed these “healthy” values due to
underlying factors including steatosis, dyslipidemia, obesity and med-
ications unrelated to CHB infection; therefore, these ALT values can-
not be reliably interpreted to reflect inflammation due solely to HBV
infection. Moreover, since “normal” ranges in clinical laboratories are
determined by the patient population served by that laboratory in
addition to nonstandardised assays for ALT measurement, these val-
ues will inherently vary between laboratories. The inclusion criteria
used for patients treated with nucleoside/nucleotide analog anti-viral
therapy in several phase 3 clinical trials were based on > ULN ALT
values derived from different clinical laboratories. Thus, the panel
recommends ALT > ULN as the threshold value for treatment based
on data from Hong Kong showing that significant inflammation and
fibrosis were noted in patients with ALT 1-1.5 9 ULN.69
In patients with an elevated serum HBV DNA above threshold
level but serum ALT ≤ ULN, further determination is necessary
before initiating anti-viral therapy. The next step is to assess the
patient’s serum albumin and platelet count. If the serum albumin is
<3.5 g/dL or the platelet count is <130 000 mm3, anti-viral therapy
can be initiated. However, if serum albumin and platelet counts are
persistently above threshold values, then testing to determine the
presence of the BCP mutation is recommended. Testing for this
mutation should be considered even in patients who are HBeAg pos-
itive, since these mutations may exist at baseline and if present, then
anti-viral therapy can be initiated. If laboratory testing is unremark-
able for hypoalbuminemia, thrombocytopenia, or BCP mutations,
then we recommend grading and staging of liver disease with liver
biopsy or assessment by noninvasive methods such as transient elas-
tography or serum markers for fibrosis. The presence of F2 fibrosis
or higher in conjunction with inflammation would be an indication to
start anti-viral therapy. In the absence of active liver inflammation
and advanced fibrosis, anti-viral therapy can be deferred; however,
the patient should be monitored at least twice annually or more fre-
quently if indicated. Other risk factors for disease progression
include first-degree relatives with HCC.70 In addition, patients with
elevated AFP levels during flares of hepatitis B (without HCC) may
be more prone to have liver disease progression.25 The presence of
any of these risk factors indicate that anti-viral therapy should be
initiated.
For patients with HBV DNA levels <2000 IU/mL and ALT >ULN,
search for other causes of ALT elevation (ie, medications, NASH,
excessive alcohol consumption, other viral infections, etc.). In
patients with HBV DNA levels <2000 IU/mL and normal ALT values,
continual evaluation should be repeated at 3-6 month intervals.
Recent publications report that successful NA therapies reduces
necroinflammation, reverses fibrosis and prevents or reverses clinical
decompensation in chronic hepatitis and cirrhosis patients.71,72 The
benefit of reducing liver complications was demonstrated in a
prospective trial of LAM in Asian patients with compensated cirrho-
sis.73 Benefit was primarily observed in patients with sustained viral
suppression; however, less significant benefit was noted in patients
who developed LAM resistance. Other studies showed that treat-
ment with anti-viral agents with low resistance profiles significantly
improved clinical outcomes in patients with decompensated cirrho-
sis.71,74 Furthermore, a recent report indicated that the risk of HCC
is significantly increased in patients with HBV-related cirrhosis with
low viral loads.75 Based on these findings, patients with cirrhosis
who have any detectable level of HBV DNA should receive lifelong
anti-viral therapy regardless of HBeAg status or ALT values. Patients
with compensated cirrhosis with undetectable HBV DNA should
have tests for ALT and HBV DNA every 3 months. Patients with
decompensated cirrhosis should be started on anti-viral therapy and
immediately referred to a liver transplant centre.
7 | ANTI-VIRAL THERAPY
7.1 | Current treatments for HBV infection
There are currently seven drugs licensed by the FDA for the treat-
ment of CHB infection, including standard interferon alfa-2b, LAM,
ADV, pegylated interferon alfa-2a, telbivudine, entecavir, tenofovir
disoproxil fumarate (TDF), and tenofovir alafenamide fumarate (TAF),
which represents a prodrug of the currently approved formulation of
tenofovir. Interferon alfa-2b is no longer used in the USA for the
treatment of HBV infection. LAM, ADV, and telbivudine are consid-
ered second line agents and a summary of their effectiveness in
HBV treatment is described in Data S7. The preferred or first-line
agents for the treatment of CHB infection include entecavir, TDF,
and pegylated interferon alfa-2a,46 although the latter is uncom-
monly used in the USA. TAF was recently approved for use in the
USA in 2016 and also may be considered as a first line treatment for
CHB. In this section, we review key data governing the efficacy of
TABLE 2 Recommendations for anti-viral therapy in HBeAg
positive and HBeAg negative chronic hepatitis B patients
Clinical stage HBeAg HBV DNA Comments
Quality of
evidence
Immune tolerant + >2000 IU/mL Insufficient
evidence to
warrant
treatment
IIb C-EO
Low replication
carrier
 <2000 IU/mL Insufficient
evidence to
warrant
treatment
IIb C-EO
Chronic
hepatitisa
+/ >2000 IU/mL See algorithm IA
Cirrhosis +/ Detectableb Treat IA
Decompensated
cirrhosis
+/ Detectableb Treat I B-NR
Hepatocellular
carcinoma
+/ Detectableb Treat IIb C-EO
EO, expert opinion; NR, Non randomised studies.
aDiffers from APASL and AASLD guidelines.
bOption to treat if HBV DNA undetectable.
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approved agents with regard to clinical endpoints including normali-
sation of ALT, suppression of HBV DNA to undetectable levels,
HBeAg seroconversion, and HBsAg seroconversion. A summary of
the four current agents for anti-viral treatment in Asian CHB
patients is shown in Table 3.
7.1.1 | Pegylated interferon Alfa-2a
Pegylated interferon alfa-2a (Pegasys) was licensed by the FDA for
the treatment of HBV infection in 2005. Two phase 3 clinical trials
provided the evidence base supporting approval. In the first, Lau
et al50 reported the findings in 814 HBeAg positive patients which
showed that after 48 weeks of treatment, pegylated interferon alfa-
2a alone and pegylated interferon alfa-2b plus LAM were superior to
LAM alone in achieving HBeAg seroconversion (32% vs 27% vs
19%, P = 0.02) and suppression of HBV DNA to <100 000 copies/
mL (32% vs 34% vs. 22%, P = 0.003). Eight patients in each of the
pegylated interferon groups achieved HBsAg seroconversion,
whereas no patients treated with LAM alone achieved this endpoint
(3% vs. 3% vs. 0%, P = 0.004). In the second, Marcellin et al76
reported the findings in 537 HBeAg negative patients which showed
that after 48 weeks of treatment, pegylated interferon alfa-2b alone
and pegylated interferon alfa-2b plus LAM were superior to LAM
alone in achieving normalisation of serum ALT (59% vs 60% vs 44%,
P = 0.004), and suppression of HBV DNA to <400 copies/mL (19%
vs 20% vs 7%, P < 0.001). Seven patients in the pegylated interferon
alone group and five patients in the pegylated interferon plus LAM
group achieved HBsAg seroconversion, whereas no patients treated
with LAM achieved this endpoint (4% vs 2.8% vs 0%, P = 0.029).
Additional studies combined pegylated interferon alfa-2a with NAs
such as LAM,77 ADV,78 telbivudine,79 entecavir,80 and TDF,81 but
due to limited evidence, these regimens have not been incorporated
into practice guidelines.
7.1.2 | Entecavir
Entecavir is an oral NA which was licensed by the FDA for the
treatment of HBV infection in 2005. Two phase 3 clinical trials
provided the evidence base supporting FDA approval. In the first,
Chang et al82 reported the findings in 715 treatment-na€ıve HBeAg
positive patients which showed that after 52 weeks of treatment,
entecavir was superior to LAM in achieving the primary efficacy
endpoint of histological improvement (72% vs 62%, P = 0.009), as
well as in achieving secondary endpoints including undetectable
HBV DNA (67% vs 36%, P < 0.001), normalisation of serum ALT
(68% vs 60%, P = 0.02), and mean log reduction in serum HBV
DNA between baseline and week 48 (6.9 vs 5.4 log copies/mL,
P < 0.001).82 No statistical difference was observed in HBeAg
seroconversion rates (21% vs 18%, P = 0.33). In the second, Lai
et al83 reported the findings in 648 HBeAg negative patients
which showed that after 52 weeks of treatment, entecavir was
superior to LAM in achieving the primary efficacy endpoint of his-
tological improvement (70% vs 61%, P = 0.01), as well as in
achieving secondary endpoints including undetectable HBV DNA
(90% vs 72%, P < 0.001), normalisation of serum ALT (78% vs
71%, P = 0.045), and mean log reduction in serum HBV DNA (5.0
vs 4.5 log copies/mL, P < 0.001).83 Multiple studies have con-
firmed the long-term safety and efficacy of entecavir in USA
cohorts with sustained virological suppression to undetectable
levels and histological improvement.84,85
7.1.3 | Tenofovir disoproxil fumarate (TDF)
Tenofovir disoproxil fumarate is an oral nucleotide analogue, which
was licensed by the FDA for the treatment of HBV infection in
2008. Two phase 3 clinical trials provided the evidence base sup-
porting FDA approval. Marcellin et al86 reported the findings of both
phase 3 clinical trials in which 276 treatment-na€ıve HBeAg positive
patients and 375 treatment-na€ıve HBeAg negative patients were
randomised to receive 48 weeks of treatment with either TDF
300 mg daily or ADV 10 mg daily. TDF was superior to ADV in
achieving the primary efficacy endpoint of suppression of HBV DNA
to <400 copies/mL (69 IU/mL) and histological improvement in both
HBeAg positive (66% vs 12%, P < 0.001) and HBeAg negative
patients (71% vs 49%, P < 0.001). TDF was also superior to ADV for
other secondary endpoints including undetectable HBV DNA (76%
vs 13%, P < 0.001 in HBeAg positive patients and 93% vs 63%,
P < 0.001 in HBeAg negative patients). TDF was associated with
higher rates of normalisation of serum ALT (68% vs 54%, P = 0.03)
in HBeAg positive patients, but not in HBeAg negative patients
(76% vs 77%, P = 0.86). Rates of HBeAg seroconversion were not
statistically different between TDF and ADV (21% vs 18%,
P = 0.36), although TDF was associated with a higher rate of HBsAg
loss (3.2% vs 0%, P = 0.02). Long-term studies have further con-
firmed the sustained safety and efficacy of TDF including virological
suppression and histological regression at 5 years of therapy.87-89
7.1.4 | Tenofovir alafenamide (TAF)
Tenofovir alafenamide represents a prodrug which enhances deliv-
ery of active tenofovir to hepatocytes and reduces circulating levels
of tenofovir relative to TDF, and thereby decreases the risk of
renal dysfunction and bone mineral density (BMD) decline. Two
phase 3 clinical trials provided the evidence base supporting FDA
approval. Chan et al90 reported the results in 873 HBeAg positive
patients randomised 2:1 to TAF 25 mg daily (n = 581) or TDF
300 mg daily (n = 292) for a period of 96 weeks. Based on a non-
inferiority study design, no difference was observed between
groups in the primary therapeutic endpoint of suppression of HBV
DNA to <29 IU/mL (64% TAF vs 67% TDF, P = 0.25), or secondary
endpoints such as normalisation of serum ALT (72% TAF vs 67%
TDF, P = 0.18), HBeAg loss (14% TAF vs TDF 12%, P = 0.47),
HBeAg seroconversion (10% TAF vs 8% TDF, P = 0.32) or HBsAg
loss (<1% TAF vs <1% TDF, P = 0.52). Although total AEs, SAEs,
and discontinuations due to AEs were similar between groups,
fewer patients on TAF experienced a > 3% decrease in bone
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mineral density at week 48 in the spine (18% TAF vs 38% TDF,
P < 0.001) and hip (8% TAF vs 24% TDF, P < 0.001), and fewer
changes were observed in bone turnover markers. In addition, TAF
was associated with less change in serum creatinine (0.009 vs
0.026, P = 0.02) and fewer patients with decline in the estimated
glomerular filtration rate (eGFR) to <50 mL/min (0 vs 2%,
P = 0.004). Buti et al91 reported the results in 425 HBeAg negative
patients randomised 2:1 to TAF 25 mg daily (n = 285) or TDF
300 mg daily (n = 140) for a period of 96 weeks. Based on a non-
inferiority study design, no difference was observed between
groups in the primary therapeutic endpoint of suppression of HBV
DNA to <29 IU/mL (94% TAF vs 93% TDF, P = 0.47), or secondary
endpoints such as normalisation of serum ALT (83% TAF vs 75%
TDF, P = 0.076). Although total AEs, SAEs, and discontinuations
due to AEs were similar between groups, fewer patients on TAF
experienced a > 3% decrease in bone mineral density at week 48
in the spine (22% TAF vs 39% TDF, P < 0.001) and hip (10% TAF
vs 33% TDF, P < 0.001), and fewer changes were observed in
bone turnover markers. The mean change in serum creatinine at
week 48 was minimal in both groups (TAF 0.01 mg/dL vs TDF
0.02 mg/dL, P = 0.32), but patients receiving TAF, had a smaller
reduction in creatinine clearance (median change in eGFR
1.8 mL/min vs 4.8 mL/min, P = 0.04), with minimal changes in
markers of proximal renal tubular function. Based on a superior
TABLE 3 Virological, biochemical and histological responses to anti-viral agents in treatment naive patients with CHB
Asian
patients Trial endpoints
First line agents
Pegylated interferon
alfa 2a (up to 45 weeks)
Entecavir
(up to 240 weeks)
Tenofovir
(up to 192 weeks)
Tenofovir
alafenamide
(up to 48 weeks)
HBeAg() HBV DNA Year 1 undetectable
HBV DNA
19% 93% 82% (ITT) 94%
Long-term undetectable
DNA
N/A 98.3% 97%
ALT Year 1 ALT
normalisation
59% 76% 72% 83%
Long-term ALT
normalisation
N/A 85.7% 86% (combined with
e-pos patients) @
192 weeks
HBsAg loss /
sero-conversion
Year 1 HBsAg
sero-conversion
0/0% 0/0% 0%/0%
Long-term HBsAg
loss/sero-conversion
0/0% 0/0%
Histological
Improvement
Year 1 histological
improvement
N/A 68% 77%
Long-term histological
improvement
N/A 100% N/A
HBeAg(+) HBV DNA Year 1 undetectable
HBV DNA
14% @ 24 wk post Rx 69% (<300 c/mL) 85% (ITT)
(<400 copies/mL)
64% (<29 IU/mL)
Long-term undetectable
HBV DNA
N/A 95% 97%
ALT Year 1 ALT
normalisation
41% @ 24 wk post Rx 63% 72% 72%
Long-term ALT
normalisation
N/A 76% 86%
HBeAg loss/
seroconversion
Year 1 HBeAg loss/
seroconversion
31%@24 wk post Rx 16/16% 17/17% 14/10%
Long-term HBeAg loss/
sero-conversion
41% @ 48 wk post Rx 40/18% 35/26%
HBsAg loss/
seroconversion
Year 1 HBsAg
seroconversion
2% @ 24 wk post Rx 0.5% 0/0% <1%/0%
Long-term HBsAg loss /
sero-conversion
N/A 2.9% in genotype B
0.9% in genotype C
2.28%
Histological
Improvement
Year 1 histological
improvement
38% 71% 77%
Long-term histological
improvement
N/A 100% N/A
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safety profile and non-inferiority of efficacy endpoints, TAF repre-
sents an attractive alternative to TDF in the treatment of CHB.
7.1.5 | Treatment for decompensated cirrhosis
The efficacy and safety of oral NAs has been studied in patients
with decompensated cirrhosis, although the evidence base is limited
with historical anti-viral agents.92 Interferon alfa-2b and pegylated
interferon alfa-2a are contraindicated in this population. Due to
superior potency and low rates of virological resistance, and more
robust evidence in prospective trials,71,74,93 either entecavir or TDF
are preferred agents for use in patients with decompensated cirrho-
sis. Long-term studies documenting the impact of anti-viral therapy
in this population on both pre-transplant and post-transplant clinical
outcomes (eg, hepatic decompensation, hospitalisations, HCC, liver-
related and all-cause mortality) remain limited and would be helpful
in clarifying the role and timing of treatment in this population.
8 | MONITORING HBV TREATMENT
Prior to initiating anti-viral treatment, patients should be informed
that therapy is long-term and adherence and regular follow-up visits
are essential. Anti-viral medications for hepatitis B are usually well
tolerated with minimal side effects.11, 93-97 Timely prescription refills
and appropriate patient support will improve patient compliance and
treatment outcomes.
8.1 | Laboratory monitoring
After initiating anti-viral therapy, liver tests should be performed
every 3 months until serum ALT levels are within normal limits and
thereafter at 3-6 month intervals. ALT flares may occur after initia-
tion of treatment, but usually do not require discontinuation of med-
ication. Renal impairment including cases of acute renal failure and
Fanconi syndrome (renal tubular injury) with hypophosphatemia have
been reported in a few cases treated with TDF.93 If clinically indi-
cated, serum creatinine, estimated creatinine clearance, phosphorus
and urine glucose and protein should be measured.11,93,94 Similar
assessment of renal function also is recommended for patients trea-
ted with TAF.98 In patients receiving pegylated interferon therapy,
complete blood cell counts including absolute neutrophil and platelet
counts, and thyroid function testes are required. Serum HBV DNA
should be measured using a sensitive PCR test with preferred detec-
tion limit of 20-50 IU/mL every 3 months until undetectable, and
then every 3-6 months thereafter. HBeAg positive patients on anti-
viral treatment should have tests for HBeAg every 6 months until
seronegative before initiating anti-HBe testing. HBsAg should be
tested every 12 months after seroconversion from HBeAg to anti-
HBe positive.11,93 Although on-treatment HBsAg clearance is rare in
Asian patients, it is recommended that testing for HBsAg be per-
formed every 12 months after sustained suppression of HBV DNA
in HBeAg negative patients.94 Recent reports have indicated HBsAg
quantification may be useful in predicting HBV treatment responses,
but such tests are not widely available at present.99
8.2 | Treatment duration and endpoints
Hepatitis B virus treatment duration with anti-viral regimens is
dependent on the clinical stage of disease and HBeAg status.100 The
decision to discontinue anti-viral therapy should be made only after
careful assessment of patients’ compliance for continued monitoring
since only 38% of patients will maintain their clinical endpoints
within 36 months of follow-up, as described in a recent meta-analy-
sis of 25 studies for NA cessation.101
The optimal duration of anti-viral therpy for HBeAg positive and
HBeAg negative chronic hepatitis patients without cirrhosis is
unknown. Also, risk factors associated with relapse after stopping anti-
viral therapy have not yet been identified. However, based on current
information, our recommendations for duration of treatment and the
importance of close post-treatment monitoring are described below.
8.2.1 | HBeAg positive CHB Infection
For HBeAg positive CHB infection without histological or imaging
evidence of advanced CHB infection, it had been recommended that
anti-viral treatment may be discontinued with at least 12-24 months
of consolidation treatment after HBeAg seroconversion.102 However,
studies have indicated that HBV progression may continue after
HBeAg seroconversion, and a substantial number of patients who
discontinue therapy after completing consolidation therapy can
experience recurrent viraemia, biochemical flares, and clinical
relapse.103 In a retrospective study of 124 Chinese patients treated
with LAM who achieved HBeAg serconversion with HBV DNA <200
copies/mL, the relapse rates (HBeAg servconversion) at 1 and
2 years post-treatment were 54% and 68% respectively.104 In a
recent report in HBeAg positive Asian American patients who dis-
continued anti-viral therapy after loss of HBeAg and development of
anti-HBe, 90% developed recurrent viraemia, 38% had elevated ALT
levels and 8% had seroreversion to HBeAg positivity.105 Another
study of HBeAg positive Chinese patients who discontinued LAM
after HBeAg seroconversion showed that all patients experienced
reappearance of HBV DNA and 44% of patients had ALT flares.106
Due to the risk of recurrent viraemia and biochemical flares after
discontinuing therapy, a long-term anti-viral treatment is now recom-
mended until 6-12 months after HBsAg clearance or HBsAg sero-
conversion.103-105 However, if treatment discontinuation is being
considered after HBeAg seroconversion and a period of consolidated
treatment but before HBsAg clearance, we recommend that the
patient meet the following criteria:
1. Histological or elastography evidence of hepatic fibrosis stage <2
2. Close post-treatment monitoring at monthly intervals for the first
3 months, and then 3-6 months thereafter. Close attention for
recurrent viraemia, with or without HBeAg seroreversion, ALT
elevations and clinical relapse will determine if anti-viral therapy
needs to be reinstituted. Recently, in patients treated with
1190 | TONG ET AL.
entecavir, HBsAg titres of ≤2 to ≤2.5 log10 IU/mL at the time of
HBeAg seroconversion were predictive of a low virological
relapse rate in Asian patients.107,108 Further studies quantifying
HBsAg levels will be useful in confirming these findings.
8.2.2 | HBeAg negative CHB infection
Although NA treatment is highly effective in suppressing HBV replica-
tion, it does not eliminate HBV infection. The recurrent viraemia rate
is high even after a long-term treatment-induced suppression of HBV
replication, and may result in biochemical flare or even hepatic decom-
pensation. A recent systematic review study on 1732 HBeAg negative
CHB-infected patients who received anti-viral treatment reported that
1-year off-therapy virological relapse and clinical relapse occurred in
<70% and <50% of the patients, respectively, and <40% of the
patients received re-treatment.100 In patients who received 5 years of
treatment with ADV, up to 60% had virological relapse with elevated
ALT levels after stopping treatment.109 Recently, two Asian studies
also showed high relapse rates after ETV therapy. One reported a viro-
logical relapse rate of 57.8%, a clinical relapse rate of 45.2%, and a re-
treatment rate of 35.8% after 2 years of ETV therapy.110 Another
study reported a virological relapse rate of 91.4%, and a retreatment
rate of 88.5% after 3 years of ETV therapy.111 Therefore, for HBeAg
negative CHB patients with histological or imaging evidence of
advanced CHB infection, indefinite NA treatment is recommended to
maintain HBV DNA suppression. However, if stopping anti-viral ther-
apy is being considered, then close follow-up with frequent laboratory
testing to detect relapse and reinstitution of anti-viral treatment is
strongly recommended. Although HBsAg loss or HBsAg seroconver-
sion is desired, it is rarely achievable in Asian patients. If HBsAg clear-
ance does occur, NA treatment discontinuation with close follow-up
may be considered.
8.2.3 | Cirrhosis
Discontinuation of anti-viral treatment in patients with cirrhosis car-
ries a risk of hepatic decompensation or even liver failure.11,93 Fur-
thermore, a large retrospective study indicated that even among
patients already on anti-viral therapy, a low-level viraemia, defined
as persistent or intermittent episodes of HBV DNA > than the lower
detection limit of 12 IU/mL but, <2000 IU/mL was associated with a
higher risk of developing HCC, particularly in patients with cirrhosis,
when compared to those who maintained virological response with
persistently undetectable HBV DNA levels.112 It is recommended
that all patients with baseline clinical evidence of compensated or
decompensated HBV cirrhosis, regardless of HBeAg and HBV DNA
status, remain on a life-long course of anti-viral therapy.
8.2.4 | Monitoring and managing anti-viral
treatment nonresponse or suboptimal response
As summarised in Table S5, primary virological non-response to anti-
viral treatment is defined as a <1 log10 drop from baseline after
3 months of therapy, whereas a suboptimal response is defined as a
>1 log10 decline, but detectable HBV DNA after 3-6 months of treat-
ment. Primary nonresponse or suboptimal response may occur if:
1. The patient is noncompliant to the treatment regimen, or is hav-
ing difficulty with prescription refills.
2. The anti-viral agent had limited potency, or
3. There is pre-existing anti-viral resistance.
These potential scenarios must be determined during clinic visits.
8.2.5 | Virological breakthrough or rebound and
anti-viral resistance
Virological breakthrough is defined as a > 1 log10 increase from the
nadir HBV DNA (IU/mL) level while on therapy in compliant patients.
Virological rebound is defined as an increase in serum HBV DNA to
>20 000 IU/mL or above the pre-treatment baseline level during
continued therapy. Both virological breakthrough and rebound may
occur after achieving an initial virological response. Once noncompli-
ance is excluded, virological breakthrough and rebound usually
denotes anti-viral resistance.
Hepatitis B virus anti-viral resistance can be divided into two cat-
egories; (1) genotypic resistance which refers to substitutions at con-
served sites within the polymerase gene targeted by the drug, and
(2), phenotypic resistance which refers to a reduction in the in vitro
susceptibility to anti-viral agents associated with genotypic resis-
tance.113 Anti-viral resistance can be single, multiple, or cross-
resistant. Cross-resistance is defined as decreased susceptibility to
more than one HBV anti-viral drug conferred by the same amino
acid substitution or combination of amino acid substitutions. The
clinical consequences of drug resistance include a reduced rate of
HBeAg seroconversion, reversal of virological and histological
improvement, an increased rate of disease progression and severe
exacerbations especially in patients with cirrhosis.114,115 The poten-
tial exists for transmission of drug resistant HBV, and for the appear-
ance of HBsAg mutations that may lead to vaccine failure.116,117
It is recommended that any patient with a virological break-
through or rebound undergo drug resistance analysis. Currently,
there are two types of genotypic HBV resistance tests; direct
sequencing allowing the identification of mutations that comprise
>20% of the total HBV population, and a line probe assay that iden-
tifies resistance mutations using real-time PCR analysis with specific
probes and polymorphism analysis that allows for the identification
of mutations that comprise 5% of the total HBV population. In a
recent report, up to 40% of virological breakthroughs in CHB-
infected patients receiving NA were related to medication non-
adherence and not anti-viral genotypic resistance.118 Thus, close
counselling of patients on adherence to their anti-viral medications
as well as confirmation of virological breakthrough and drug resis-
tance testing are recommended to avoid unnecessary changes in
anti-viral mediations.
Table 4 summarises recommended therapy for anti-viral resis-
tance and cross-resistance. When a single-drug genotypic resistance
is confirmed, the preferred approach in patients with either LAM,
telbivudine, ADV or ETV resistance is to switch to TDF therapy.119
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Patients with ADV resistance may also be switched to ETV.11,93
However, switching to ADV is not recommended in patients who
developed renal dysfunction during ADV treatment. If multidrug
resistance is identified, the combination of ETV and TDF is pre-
ferred.120 Recently, TDF genetic resistance was reported in a few
treatment experienced Korean patients.121 However, identification
of a triple mutation that confers tenofovir resistance in HBV patients
has not yet been established.
Patients with a suboptimal response to ADV may be switched to
ETV or TDF,11,93,103,122 those with suboptimal response to tel-
bivudine or LAM may be switched to TDF;11,93,119 and patients with
suboptimal response to ETV may be switched to TDF.123
9 | SPECIAL POPULATIONS
9.1 | Chronic hepatitis B infection during childhood
and adolescence
Chronic HBV infection in children is a major health problem not only
in high endemic regions, but also in Western countries with large pro-
portions of immigrants from endemic areas, as well as in cases of
international adoption from regions where HBV is prevalent.124 HBV
exposure leading to chronicity occurs either via perinatal transmission
from infected mothers or during early childhood. If immunoprophy-
laxis is not administered at birth, 90% of infants born to HBeAg posi-
tive highly viremic mothers, and 5% born to HBeAg negative mothers
will become chronic carriers.125 In addition, 25%-50% of children
exposed to HBV before 5 years of age via horizontal transmission
from non-maternal sources, ie, HBsAg positive family members, also
will become chronic carriers. When infected beyond 5 years of age
or during adolescence, 2.5%-10% become HBV carriers. HBV infec-
tion during infancy and childhood is usually clinically asymptomatic
with minimal or normal liver histological changes. However, although
rare, acute and fulminant hepatitis have been reported in Asian
infants born to HBeAg negative carrier mothers.126-128
Similar to adults, chronic HBV infection in children is classified into
four phases: the HBeAg positive immune tolerant and immune active
phases, and the HBeAg negative low replication and reactivation
phases.129 HBsAg positive children who acquired HBV by vertical
transmission or during early childhood begin in the immune tolerant
phase. In Asian HBsAg positive children, HBeAg seroconversion is
uncommon and only occurs at an annual rate of less than 2% per year
in infants less than 3 years of age, and at 4%-5% per year in children
over the age of 3 years.129 Progression to the HBeAg positive immune
active phase may occur at any age in children and is accompanied by
ALT elevation and inflammatory activity in the liver.130 In a recent
report, up to 40% of children in the HBeAg positive immune active
phase experienced seroconversion to HBeAg negative and entered
into the low replication phase.131 In the study, approximately 50% of
the children remained in the HBeAg positive immune tolerant phase
during the course of follow-up. Also, other reports showed that by
17 years of age, 25% of Asian American children and 40% of Japanese
children had experienced spontaneous HBeAg seroconversion.131,132
Progression to cirrhosis and development of HCC in HBsAg posi-
tive Asian children is rare. In a report from Taiwan, only three of
426 (0.7%) of chronic carrier children progressed to cirrhosis.133 Two
reports from Asia showed low rates of 0.5% to 1.5% for HCC devel-
opment.129,133 In one report, early HBeAg seroconversion and pres-
ence of cirrhosis were risk factors for HCC in HBsAg positive
children. The youngest reported Asian American child to develop
HCC was a 6-year-old male born to an HBeAg positive carrier
mother.127 By the age of 3 years, a liver biopsy showed cirrhosis
and seroconversion to anti-HBe positivity had already occurred.
Anti-viral treatment is recommended for children and adolescents
who are in the HBeAg positive immune active phase of CHB, with
elevated serum ALT values and HBV DNA levels >2000 IU/
mL.124,129 The primary endpoint of therapy in HBeAg positive chil-
dren is HBeAg seroconversion. Children with HBeAg negative hep-
atitis (reactivation phase) with elevated ALT levels and HBV DNA
levels >2000 IU/mL to >20 000 IU/mL also are recommended for
anti-viral treatment.124 In HBeAg negative children, the primary end-
points are reduction in HBV DNA and normalisation of ALT levels.
Children with compensated cirrhosis with any detectable HBV DNA
value should receive immediate anti-viral treatment regardless of
ALT levels or HBeAg status. The primary endpoint of treatment in
children with compensated cirrhosis is undetectable HBV DNA. Chil-
dren with decompensated cirrhosis should be immediately referred
to liver transplant centres.
At present, children in the HBeAg positive immunotolerant phase
are not recommended for treatment since anti-viral therapies have
TABLE 4 Anti-viral resistance, cross resistance and recommended therapy
NA-based resistance Common mutation sites Resistance rates Recommended therapy
LAM M204V/I/S, L180M/I, M204V/I/S, A181T/V 74% at 5 years Switch to TDF
ADV A181T/V, N236T, I233V 29% at 3 years Switch to TDF
LdT M204I/V, rtA81T/V, rtL229W/V 21.6% at 2 years Switch to TDF
ETV M204V/I, L180M, M250V, I169T 1.2% at 6 years Switch to TDF
TDF No known mutation 0% at 8 years Continue TDF
LAM+ADV A181V and N236T Variable Switch to TDF
Multiple resistance Variable combination Variable Switch to TDF + ETV
LAM, lamivudine; ADV, adefovir, LdT, telbivudine; ETV, entecavir; TDF, tenofovir.
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not been proven to be effective.124 Also, anti-viral therapy is not
recommended in children with HBeAg negative low replication (HBV
DNA <2000 IU/mL) “inactive carrier” phase.124,134 More detailed
information for the treatment of HBV in children and adolescents
are summarised in recent reports.124,129
Currently, there are five drugs that are approved for treatment
of children with CHB.124 Standard interferon is approved for use in
children ages 1-17 years. Entecavir is approved for use in children 2
to <18 years and tenofovir is recommended for use in children ≥12
to 18 years of age. Entecavir and tenofovir have low cumulative
rates of resistant variants of 2.6% and 0% respectively, and both
drugs are well tolerated with minimal side effects. Lamivudine and
adefovir are seldom used in the USA. Only nucleos(t)ide analogs
should be used in children with cirrhosis.
9.2 | HBV infection and pregnancy
Pregnant mothers with CHB infection can vertically transmit HBV to
their infants,125 and if untreated, CHB infection will develop in up to
90% of infants born to HBeAg positive mothers. The combination of
postnatal passive and active immunisation reduces the rate of MTCT
from 90% to 10%.135-137 However, even with passive-active
immunoprophylaxis, 7%-32% of infants born to carrier mothers with
HBV DNA levels ≥200 000 IU/mL (≥106 copies/mL) will still become
HBsAg positive.138-140 To reduce immunoprophylaxis failure rates
among infants born to mothers with high viral loads, anti-viral ther-
apy with TDF, LAM or telbivudine is indicated during the third trime-
ster of pregnancy.141-144 Another indication for anti-viral treatment
during pregnancy is maternal liver disease progression or reactiva-
tion, especially if clinically severe.145 Candidates for anti-viral ther-
apy during pregnancy are as follows:
1. Women with HBV DNA levels ≥200 000 IU/mL (≥106 copies/
mL) at the third trimester of pregnancy.
2. Mothers with exacerbation of ALT (>5 9 ULN of laboratory ref-
erence value), or severe fibrosis (ie, stage IV at Metavir scale;
I).146,147 Anti-viral treatment can be initiated at any time point
during pregnancy as indicated.
The use of LAM and telbivudine to reduce the transmission of
HBV from mothers with high viral loads during the third trimester
appears to be effective and well tolerated.139,141-143 However, high-
quality data are lacking. Recently, a prospective randomised control
study with TDF demonstrated that the rate of MTCT was signifi-
cantly reduced from 7% to 0% when TDF was given during the third
trimester to HBeAg positive mothers with high viral loads. The
safety profiles were comparable between the TDF-treated group and
the control group at 28 weeks of postpartum follow-up.144
Although few studies investigated the safety of using LAM or
telbivudine during the first or second trimester to control active
CHB disease, the treatment appears to be effective at normalising
ALT or reducing viraemia with a comparable safety profile146,147
Anti-viral resistance has been reported in mothers who received
LAM therapy, although this could be managed by switching to
telbivudine or TDF during pregnancy. Therefore, the authors recom-
mend the following treatment selection for mothers, and an algo-
rithm for anti-viral therapy during pregnancy is presented in
Figure 6. These recommendations are based on studies in HBsAg
positive pregnant Asian women.
1. TDF should be considered as the first line treatment option for
mothers with high viraemia and started at gestational week 30,
or earlier if maternal liver disease required treatment.
2. As the second line treatment, telbivudine may be used during
pregnancy. LAM should be limited to late second trimester or
third trimester treatment for patients with HBV DNA between 6
and 9 log10 copies/mL due to the potential for resistance and
lower potency.139,148
In a retrospective study by Pan et al, a significant reduction in
the MTCT rate of HBV was observed in HBeAg positive mothers
with high viral loads when elective caesarean section was per-
formed.149 However, further studies are warranted to confirm these
findings. Mothers with high viral loads who missed the opportunity
for third trimester anti-viral treatment may consider this option and
careful assessment of the risk-benefit ratio with the participation of
patient’s obstetrician is recommended.
For consultation on pre-conception, antepartum, or postpartum
care, and infant outcomes, the discussion may include the
following:
1. Treatment na€ıve patients with a treatment indication may consider
interferon therapy to seroconvert HBeAg prior to becoming preg-
nant if the pregnancy is planned more than 1 year in advance.
2. For patients who are receiving oral anti-viral treatment and found
to be pregnant, therapy should either be stopped or switched to
TDF if the patient was receiving non-TDF-based treat-
ment.146,147,150
3. Amniocentesis may increase the risk of HBV transmission in
mothers with viral loads >107 copies/mL. The decision to per-
form this procedure should be made with careful assessment on
the risk-benefit ratio for these mothers.151
4. As gestational diabetes, antepartum haemorrhage, and threatened
preterm labor frequently occur among HBV-infected mothers,
close monitoring with at least one HBV DNA quantitative testing
at gestational week 28 is highly recommend for assessing the risk
of HBV transmission.152
5. In mothers who prefer breast-feeding, anti-viral therapy should be
discontinued since these agents may be secreted in breast milk, and
long-term data on the safety of exposing infants to anti-viral agents
are not currently available. Stopping anti-viral treatment in mothers
after delivery for lactation appears to be safe, as significant hepatitis
flares have not been observed.153-155 Postpartum monitoring on
ALT should be performed on weeks 4 and 12.144,156,157
9.3 | HBV coinfection with HCV or HDV
Since HBV and HCV share similar routes of transmission, coinfec-
tion with either virus is detected in 7%-22% of CHB-infected
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patients. Coinfection with HCV is found predominantly among indi-
viduals at high risk for parenteral infection, including injection drug
use.158 Coinfection with HDV is often seen in those residing in
areas where HBV infection is highly endemic.159 HBV patients co-
infected with HCV or HDV are at higher risk for rapid progression
to decompensated liver disease and HCC.160,161 In dual HBV/HCV
infection, the treatment strategy should be directed towards the
dominant replicating virus, though HCV eradication should be con-
sidered if appropriate treatment is accessible.158,162,163 When
receiving direct acting anti-viral therapy for HCV infection, dual
HBV/HCV-infected patients may experience an acute exacerbation
of HBV unless anti-viral treatment for HBV is also provided.164
The response to HBV treatment with oral anti-viral agents does
not appear to be effected by concurrent HCV infection. In addition,
it has been reported that there is a risk for HBV reactivation in
patients with HCV/HBV co-infection whose HCV has been cleared
by direct acting anti-viral therapy (DAA).165 The FDA recently
issued a warning on the risk of HBV reactivation and recommend
that HCV patients should begin treatment for HBV prior to initiat-
ing DAA therapies (https://www.fda.gov/downloads/Drugs/Drug
Safety/UCM523499.pdf).
Among CHB-infected Asian patients with HDV super-infection,
lower levels of HBV DNA are common. HDV antigen or antibody
tests are often used for screening. Weekly injection of pegylated
interferon is currently used for 12-18 months to treat co-infected
patients.166 The HDV RNA PCR qualitative test is available for moni-
toring the treatment response. Sustained viral response at 6 months
post-treatment, which correlates better with long-term cure in the
absence of advanced fibrosis, is only seen in 17% of patients. How-
ever, late HDV RNA relapse may occur.166
9.4 | HBV and HIV coinfection
CHB infection affects nearly 15% of HIV-infected individuals. HIV
accelerates the course of HBV infection to end-stage liver disease with
more rapid progression of fibrosis.167,168 The treatment of HBV in
HBV/HIV co-infected patients should take into account both viruses.
Initiation of treatment for HBV infection is based on the presence of
significant fibrosis or meeting the HBV treatment criteria.169
Treatment for HBV has been shown to improve clinical out-
comes.170 In patients not requiring highly active antiretroviral ther-
apy (HAART), drugs with dual activity against HBV and HIV such as
Cirrhosis/stage IV fibrosis
or severe hepatitis flare
No Yes
Monitoring without treatment. Test HBV
DNA at end of 2nd trimester
Treatment with tenofovir throughout
pregnancy
HBV DNA <
200 000 IU/mL
(106 copies/mL)
HBV DNA ≥ 200 000 IU (106 copies)/mL or
previous child with immmunoprophylaxis failure or
threatened pre-term labor
Monitoring
without treatment
Tenofovir at
beginning of 3rd
trimester
Breatfeeding not recommended
if antiviral therapy used postpartum
All infants receive HBIG and HBV vaccination
*Recommendations based on studies
in Asian HBsAg positive women.
†Pan CQ, et al. Semin Liver Dis 2013;33:138–146
F IGURE 6 Anti-viral therapy for mothers during pregnancy*,†
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LAM, entecavir, emtricitabine, or TDF should not be used as
monotherapy since these drugs may lead to mutation selection and
development of antiretroviral resistance.171,172 Pegylated interferon
monotherapy or ADV in combination with telbivudine may have a
role in treating these patients.168,173 In contrast, TDF and emtric-
itabine or other TDF based regimens should be initiated in co-
infected patients with low CD4 counts who require HAART.169, 172
Reactivation of HBV has been observed in patients on HAART ther-
apy after immune reconstitution.174
9.5 | HBV reactivation during chemotherapy or
immunosuppressive therapy
Treatment with cancer chemotherapy or immunomodulatory agents
may induce potentially fatal hepatic flares in HBsAg positive patients
or those who are HBsAg negative but maintain a detectable level of
HBV DNA. The acute flare or “reactivation” results from immune
reconstitution directed towards the rise in HBV DNA following the
use of immunosuppressive or immunomodulating agents.175 A recent
meta-analysis of clinical trials suggested that treatment with LAM or
entecavir may prevent HBV reactivation during chemotherapy.176,177
It is recommended that Asian patients be screened for HBsAg prior
to initiation of chemotherapy or immunosuppressive therapy.
Patients who are HBsAg negative but anti-HBc positive should be
tested for HBV DNA. When the level of HBV DNA level is unde-
tectable in these patients, they may have the option of being moni-
tored closely without anti-viral therapy if a moderate or low level of
immunosuppressant therapy is used. In addition, CHB patients who
will require long-term corticosteroid therapy alone or in combination
with other immunosuppressive or anti-neoplastic medications, should
receive concomitant oral anti-viral HBV drugs.178,179 An algorithm
for selecting patients for anti-viral therapy is shown in Figure S3.
1. It is recommended that all HBsAg positive patients who require
chemotherapy or immunomodulatory agents should receive anti-
viral therapy.177
2. Among HBsAg negative but anti-HBc positive patients, anti-viral
prophylaxis is recommended when the HBV DNA level is detect-
able and the patient is to receive immunosuppressant agents such
as rituximab, or will be receiving bone marrow transplantation.180
3. For better efficacy of viral suppression and preventing ALT flares,
entecavir is preferred over LAM in patients with B cell lym-
phoma,178 or other solid tumours.181
10 | RECOMMENDATIONS
Based on the evidence above, the authors have agreed to the fol-
lowing recommendations regarding the management of CHB infec-
tion in Asian Americans:
1. For HBeAg positive or negative chronic hepatitis patients with
HBV DNA >2000 IU/mL (>104 copies/mL) and ALT > ULN, treat
with a first-line agent (entecavir, TDF, TAF) (I,A).
2. For compensated cirrhosis patients with detectable HBV DNA,
treat with entecavir, TDF or TAF. For decompensated cirrhotic
patients, entecavir or TDF are currently the agents of choice (I,A).
3. In HBeAg negative patients with HBV DNA >2000 IU/mL (>104
copies/mL) and normal ALT, a liver biopsy, transient elastography
or serum marker for fibrosis is recommended. If not available,
further stratification for risk factors including measurement of
serum albumin values and platelet counts should be conducted
prior to treatment (IIa, C-LD).
4. To monitor treatment, test for serum ALT every 3 months. Mea-
sure HBV DNA every 3 months until negative, then every 3-
6 months. Measure HBeAg every 6 months until negative, then
test for anti-HBe (I, C-LD).
5. After seroconversion from HBeAg positive to anti-HBe, test for
HBsAg every 12 months. In HBeAg negative patients, test for
HBsAg every 12 months after sustained suppression of HBV
DNA (I, C-EO).
6. Regarding monitoring for resistance, viral breakthrough with con-
firmation of single drug resistance requires switching to another
first-line oral anti-viral agent (IIa, B-NR).
7. Surveillance for HCC with alpha-fetoprotein and abdominal ultra-
sound should be performed every 6 months in HBsAg positive
patients with chronic hepatitis, cirrhosis, and for patients with a
family history of HCC (I, B-R).
8. HBsAg positive pregnant women should be tested for HBV DNA.
If the HBV DNA level is ≥ 200 000 IU/mL (≥106 copies/mL at
gestational week 28, TDF treatment is preferred and should be
initiated at gestational week 30 (I, B-R).
9. HBsAg positive patients or patients with any detectable levels of
HBV DNA requiring chemotherapy or treatment with immunomod-
ulatory agents should receive anti-viral treatment (I, B-NR).
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